TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~- Meet criteria for CAD and/or PAD~Subjects with CAD must also meet at least one of the following criteria:~* Age ≥65, or~* Age \<65 and documented atherosclerosis or revascularization involving at least 2 vascular beds, or at least 2 additional risk factors~Exclusion Criteria:~* Stroke within 1 month or any history of hemorrhagic or lacunar stroke~* Severe heart failure with known ejection fraction \<30% or New York Heart Association (NYHA) class III or IV symptoms~* Estimated glomerular filtration rate (eGFR)\<15 mL/min~* Need for dual antiplatelet therapy, other non-aspirin antiplatelet therapy, or oral anticoagulant therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban 2.5mg + Aspirin 100mg (Type: EXPERIMENTAL): Participants received rivaroxaban 2.5 mg twice daily (bid) and aspirin 100 mg once daily (od). All doses were provided in tablet form for oral administration. Participants who did not have a continuous need to take a proton pump inhibitor (PPI), were additionally randomized 1:1 to receive pantoprazole 40 mg (tablet form for oral administration, od) or matching placebo od. Participants who consented to LTOLE part received open label rivaroxaban 2.5 mg bid and aspirin 100 mg od in LTOLE part.
- Rivaroxaban 5mg + Aspirin Placebo (Type: EXPERIMENTAL): Participants received rivaroxaban 5 mg bid and aspirin placebo od. All doses were provided in tablet form for oral administration. Participants who did not have a continuous need to take a PPI, were additionally randomized 1:1 to receive pantoprazole 40 mg (tablet form for oral administration, od) or matching placebo od. Participants who consented to LTOLE part received open label rivaroxaban 2.5 mg bid and aspirin 100 mg od in LTOLE part.
- Rivaroxaban Placebo + Aspirin 100mg (Type: ACTIVE_COMPARATOR): Participants received rivaroxaban placebo bid and aspirin 100 mg od. All doses were provided in tablet form for oral administration. Participants who did not have a continuous need to take a PPI, were randomized 1:1 to receive pantoprazole 40 mg (tablet form for oral administration, od) or matching placebo od. Participants who consented to LTOLE part received open label rivaroxaban 2.5 mg bid and aspirin 100 mg od in LTOLE part.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: International Randomized Study of the TransMedics Organ Care System (OCS Lung) for Lung Preservation and Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Registered primary double-lung transplant candidate~* Age \> or equal to 18~* Signed: 1) written informed consent document and 2) authorization to use and disclose protected health information~Exclusion Criteria:~* Prior solid organ or bone marrow transplant~* Single lung recipient~* Multiple organ transplant recipient~* Chronic use of hemodialysis or diagnosis of chronic renal insufficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OCS Lung (Treatment Group) (Type: EXPERIMENTAL): The OCS Lung, which is a portable, integrated platform designed to maintain adult donor lungs in a normothermic state through continuous normothermic perfusion and ventilation, will be used to preserve and transport donor lungs.
- Cold flush and storage (Control Group) (Type: ACTIVE_COMPARATOR): Donor lungs will be preserved using cold flush and storage (control group)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~* Genetic diagnosis of SBMA with symptomatic muscle weakness~* Able to complete 2 minute timed walk~* Serum IGF-1 level less than or equal to 170 ng/mL~Key Exclusion Criteria:~* Medically treated diabetes mellitus or known history of hypoglycemia~* History of Bell's palsy~* Treatment with systemic steroids \> 10 mg/day (or equivalent dose); androgens or androgen reducing agents; systemic beta agonists; or other muscle anabolic drugs within the previous 3 months~* History of cancer, other than non-melanomatous skin cancer~* Retinopathy~* Papilledema Other protocol defined inclusion/exclusion criteria may apply

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BVS857 Part A Open label (Cohort 1) (Type: EXPERIMENTAL): Participants received single doses of 0.01 mg/kg BVS857 intravenously (i.v.) on day 1, 0.01 mg/kg BVS857 subcutaneously (s.c.) on day 15, 0.03 mg/kg BVS857 s.c. on day 29, 0.06 mg/kg BVS857 s.c. on day 43 and 0.10 mg/kg BVS857 s.c. on day 57.
- BVS857 Part A double blind (Cohort 2) (Type: EXPERIMENTAL): Participants received single doses of 0.03 mg/kg BVS857 i.v on day 1, 0.03 mg/kg BVS857 s.c. on day 15, 0.06 mg/kg BVS857 s.c. on day 29, 0.10 mg/kg BVS857 s.c. on day 43 and 0.10 mg/kg BVS857 s.c. on day 57. (BVS857 concentrations differed on days 43 and 57.)
- Placebo Part A double blind (Cohort 2) (Type: PLACEBO_COMPARATOR): Participants received single doses of matching placebo i.v. on day 1 and matching placebo s.c. on days 15, 29, 43 and 57.
- BVS857 Part B open-label (Cohort 4) (Type: EXPERIMENTAL): Participants received 0.1 mg/kg BVS857 i.v. weekly for 12 weeks.
- BVS857 Part B double blind (Cohort 5) (Type: EXPERIMENTAL): Participants received 0.06 mg/kg (maximum 6 mg) BVS857 i.v. weekly for 12 weeks.
- Placebo Part B double blind (Cohort 5) (Type: PLACEBO_COMPARATOR): Participants received matching placebo i.v. to BVS857 weekly for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Valacyclovir vs. Acyclovir as HSV-2 Suppressive Therapy: Effect on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 seropositive~* Not on HIV-1 antiretroviral therapy nor planning to initiate antiretroviral therapy during the study period~* CD4 cell count \>250 cell/µL~* Not otherwise eligible for antiretroviral therapy according to Uganda national guidelines~* Detectable HIV-1 plasma viral load~* HSV-2 seropositive~* Not intending to move out of the area for the duration of study participation.~* Able to participate in the study at the Partners in Prevention site in Thika, Kenya~Exclusion Criteria:~* Known history of adverse reaction to acyclovir, valacyclovir, or famciclovir.~* Planned use of acyclovir, valacyclovir, or famciclovir~* Use of ganciclovir, foscarnet, or cidofovir~* Known medical history of seizures~* Serum creatinine \>1.5 mg/dL~* AST or ALT \>3 times upper limit of normal~* Hematocrit \<30 %~* Absolute neutrophil count \<1000~* Platelet count \<75,000~* History of thrombotic microangiopathy~* Any other condition which, in the opinion of the principal investigator, may compromise the ability to follow study procedures and complete the study~* Participation in another HIV therapeutics trial~* For women, pregnancy as confirmed by a urine pregnancy test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- acyclovir (Type: ACTIVE_COMPARATOR): acyclovir 400 mg orally twice daily
- valacyclovir (Type: ACTIVE_COMPARATOR): valacyclovir 1.5 g orally twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically confirmed CD30-positive hematologic malignancy.~* Patients with HL must have failed systemic chemotherapy either as induction therapy for advanced stage disease or salvage therapy after initial radiotherapy for early stage disease and were ineligible for, refused treatment by, or previously received stem cell transplant.~* Patients must have measurable disease of at least 10mm as documented by radiographic technique.~* Must be at least 18 years of age.~Exclusion Criteria:~* Patients with current diagnosis of pcALCL (systemic ALCL eligible).~* Patients with history of allogeneic stem cell transplant.~* Patients who have had previous treatment with any anti-CD30 antibody.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Adalimumab in Patients With Axial Spondyloarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with inadequate response to \>/= 1 non-steroidal anti-inflammatory drugs (NSAIDs)~* Chronic back pain with onset \< 45 years of age~* Magnetic resonance imaging (MRI) indicating active sacroiliitis or positive human leukocyte antigen-B27 (HLA-B27) blood test in addition to meeting spondyloarthritis clinical criteria~* Negative purified protein derivative (PPD) test and chest x-ray performed at Baseline visit must be negative~* Ability to administer subcutaneous injections~* General good health otherwise~Exclusion Criteria:~* Prior anti-tumor necrosis factor (TNF) therapy~* Psoriasis or psoriatic arthritis~* Fulfillment of modified New York criteria for ankylosing spondylitis~* Recent infection requiring treatment~* Significant medical events or conditions that may put patients at risk for participation~* Females who are pregnant or breast-feeding or considering becoming pregnant during the study~* History of cancer, except successfully treated skin cancer~* Recent history of drug or alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- Open-label Adalimumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* With ≥ 1 diagnosis for IPF (the International Classification of Diseases, Ninth Revision, Clinical Modification \[ICD-9-CM\] codes 516.3, 516.31, 515, or ICD-10-CM codes J84.112) in the EMR between October 1, 2013 to April 30, 2018~* With ≥ 1 prescription for nintedanib between October 1, 2014 and April 30, 2018 (the selection window)~* The date of the first prescription will be defined as the index date~* With ≥ 1 record in the EMR database during the 12 months prior to the index date (the pre-index period)~* With ≥ 1 diagnosis of IPF during the 12 months prior to the index date~* Age ≥ 40 on the index date~* IQVIA will explore also requiring ≥ 1 chest CT scan before first IPF diagnosis during the pre-index period~Exclusion Criteria:~* With ≥ 1 diagnosis of other known causes of interstitial lung disease (ILD) on the date of or after the first IPF diagnosis during the pre-index period~* Other known causes of ILD include conditions such as systemic sclerosis, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, polymyositis, Sjögren disease, and hypersensitivity pneumonitis (ICD-9-CM codes 135, 237.7, 272.7, 277.3, 277.8, 446.21, 446.4, 495, 500-505, 506.4, 508.1, 508.8, 516.0, 516.1, 516.32-516.37, 516.2, 516.8, 516.9, 517.0, 517.2, 517.8, 518.3, 555, 710.0, 710.0-710.4, 714.0, 714.81, 720, and 759.5, or ICD-10-CM equivalent codes)~* With ≥ 1 prescription for nintedanib prior to the index date~* With ≥ 1 prescription for pirfenidone prior to or on the index date

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subjects with Idiopathic Pulmonary Fibrosis (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Therapy in Patients With Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Meet DSM-IV criteria for major depression with a HAMD-17 rating scale score of at least 18 at visit 1~* Adult men or women, 18 years of age or older~* Must be able to swallow capsules~* Laboratory results must show no clinically significant abnormalities~* If suicidal ideation is present, the investigator should assess its severity and the potential need for other interventions and determine whether these are compatible with study participation~Exclusion Criteria:~* Have a documented history of Bipolar I or II disorder, or of psychosis.~* Have a history of any seizure disorder (other than febrile seizures) or patients who have taken (or are currently taking) anticonvulsants for seizure control.~* Have a history of ADHD~* Have a history of severe allergies to more than 1 class of medications or multiple adverse drug reactions~* Are currently using alcohol, drugs of abuse, or any prescribed or over-the-counter medication in a manner which the investigator considers indicative of abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Panel A and B: Male and female subjects (non-smokers) ages 6 to 17 with a history of migraines~* Panel C: Male subjects (non-smokers) ages 12 to 17 with a history of migraines~* Subject has a history of migraine headaches, and is not experiencing a migraine on the day of study drug administration~Exclusion Criteria:~* Subject has no history of migraine headaches~* Taking medications that are monoamine oxidase inhibitors (MAOI) and selective serotonin reuptake inhibitors (SSRI)~* Subject has a condition which, in the opinion of the investigator, may interfere with optimal participation in the study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Panel A Rizatriptan (Type: EXPERIMENTAL): Subjects allocated to Panel A and randomized to receive a single dose of rizatriptan 5 mg orally disintegrating tablet (ODT) on Day 1.~Subjects weighing 20-39 kg were allocated to Panel A.
- Panel A Placebo (Type: PLACEBO_COMPARATOR): Subjects allocated to Panel A and randomized to receive a single dose of rizatriptan 5 mg orally disintegrating tablet (ODT) placebo on Day 1.~Subjects weighing 20-39 kg were allocated to Panel A.
- Panel B Rizatriptan (Type: EXPERIMENTAL): Subjects allocated to Panel B and randomized to receive a single dose of rizatriptan 10 mg orally disintegrating tablet (ODT) on Day 1.~Subjects weighing 40 kg and above were allocated to Panel B.
- Panel B Placebo (Type: PLACEBO_COMPARATOR): Subjects allocated to Panel B and randomized to receive a single dose of rizatriptan 10 mg orally disintegrating tablet (ODT) placebo on Day 1.~Subjects weighing 40 kg and above were allocated to Panel B.
- Panel C Rizatriptan (Type: EXPERIMENTAL): Subjects allocated to Panel C and randomized to receive a single dose of rizatriptan ODT on Day 1. Subjects in Panel C weighing 20-39 kg received a 5 mg dose and subjects weighing 40 kg and above received a 10 mg dose.~Panel C was added to the study by amendment to increase the number of male subjects in the 12-17 year old age group.
- Panel C Placebo (Type: PLACEBO_COMPARATOR): Subjects allocated to Panel C and randomized to receive a single dose of rizatriptan ODT placebo on Day 1. Subjects in Panel C weighing 20-39 kg received a 5 mg placebo dose and subjects weighing 40 kg and above received a 10 mg placebo dose.~Panel C was added to the study by amendment to increase the number of male subjects in the 12-17 year old age group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Candesartan Versus Propranolol for Migraine Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 to 65 years~* retrospectively have ≥ 2 migraine attacks per month during the last 3 months~* during the baseline period have ≥ 2 migraine attacks~* debut of migraine at least one year prior to inclusion~* start of migraine before age 50 years.~Exclusion Criteria:~* interval headache not distinguishable from migraine~* chronic tension-type headache or other headache occurring on ≥ 15 days/month~* pregnancy, nursing or inability to use contraceptives~* heart conduction block on ECG or significant ECG abnormality on inclusion~* heart rate \< 54 after 3 minutes rest~* previous or present asthma, diabetes; decreased hepatic or renal function~* hypersensitivity to active substance~* history of angioneurotic edema~* significant psychiatric illness~* use of daily migraine prophylactics less than 4 weeks prior to start of study~* having tried ≥ 3 prophylactic drugs against migraine during the last 10 years~* previous use of propranolol or candesartan in adequate doses~* previous discontinuation of either Atacand or Inderal Retard (or another beta blocker) due to side effects~* current use of antihypertensive medication~* require use of rizatriptan (Maxalt) 10 mg tabl.~* subjects requiring detoxification from acute medication (ergotamines, opioids)~* patients who consistently fail to respond to any acute migraine medication~* patients with alcohol or illicit drug dependence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 Candesartan (Type: EXPERIMENTAL): None
- 2 propranolol (Type: ACTIVE_COMPARATOR): None
- 3 Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy in Treating Patients With Stage II Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate within the past 6 months~  * Clinical stage T1-2c~* Combined Gleason score 2-6~* Prostate-specific antigen (PSA) \< 10 ng/mL within the past 6 months~  * PSA evaluated at least 10 days after prostate biopsy~ * For patients who received finasteride, PSA evaluated at least 30 after completion of finasteride~ * For patients who received dutasteride, PSA evaluated at least 90 after completion of dutasteride~* No regional lymph node involvement~* No distant metastases~PATIENT CHARACTERISTICS:~* Zubrod performance status 0-1~* No unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months~* No transmural myocardial infarction within the past 6 months~* No acute bacterial or fungal infection requiring IV antibiotics~* No chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study treatment~* No hepatic insufficiency resulting in clinical jaundice and/or coagulation defects~* No known AIDS~* No prior or concurrent lymphomatous/hematogenous malignancy or other invasive malignancy except nonmelanomatous skin cancer or any other cancer for which the patient has been continually disease-free for ≥ 5 years (e.g., carcinoma in situ of the bladder or oral cavity)~* No other severe, active comorbidity~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior radical prostatectomy or cryosurgery for prostate cancer~* No prior hormonal therapy, including any of the following:~  * Luteinizing hormone-releasing hormone agonists (e.g., goserelin or leuprolide)~ * Antiandrogens (e.g., flutamide or bicalutamide)~ * Estrogens \[e.g., diethylstilbestrol (DES)\]~ * Surgical castration (bilateral orchiectomy)~* No prior pelvic radiotherapy or prostate brachytherapy~* No prior or concurrent cytotoxic chemotherapy for prostate cancer~* At least 30 days since prior finasteride~* At least 90 days since prior dutasteride~* No concurrent neoadjuvant or adjuvant hormonal therapy~* Concurrent warfarin or other blood-thinning agents allowed

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Conventional 3D-CRT (Type: ACTIVE_COMPARATOR): Conventional 3D-CRT or IMRT to 73.8 Gy in 41 fractions
- Hypofractionated 3D-CRT (Type: EXPERIMENTAL): Hypofractionated 3D-CRT or IMRT to 70 Gy in 28 fractions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete